Home | Welcome to Contract Pharma   
Last Updated Tuesday, January 27 2015

Print

Breaking News

Kristin Brooks
January 8, 2014
Will utilize ImmTAC technology to develop cancer therapies  Read More »
Kristin Brooks
January 8, 2014
Supports more than 300 successful NDAs  Read More »
Kristin Brooks
January 8, 2014
Gains therapeutic franchises in $2.9 billion buyout  Read More »
Gil Roth
January 7, 2014
Alitair, Celgene, Erytech, Galena, Neurocrine, Orexigen, Shield, TeaRx  Read More »
Kristin Brooks
January 7, 2014
To explore relevant genotypes aimed at identifying novel drug targets  Read More »
Kristin Brooks
January 7, 2014
Forms strategic alliance with BioTelemetry division  Read More »
Kristin Brooks
January 7, 2014
Sedlack to identify business opportunities and compound partnerships  Read More »
Kristin Brooks
January 7, 2014
Expands integrated commercialization programs for U.S. customers  Read More »
Kristin Brooks
January 7, 2014
Dinsmore brings extensive discovery and development expertise  Read More »
Kristin Brooks
January 7, 2014
Lam brings 28 years of experience  Read More »
Kristin Brooks
January 7, 2014
To develop and commercialize DURECT’s Eladur  Read More »
Kristin Brooks
January 7, 2014
R&D collaboration completes first successful year  Read More »
Kristin Brooks
January 7, 2014
Cites new R&D paradigms as essential  Read More »
Gil Roth
January 6, 2014
Alkermes, DiaVacs, Kala, Oxygen Biotherpeutics, Peregrine, TauRx  Read More »
Kristin Brooks
January 6, 2014
Wooster brings extensive oncology experience  Read More »



Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On